Wai Yuen Tong Medicine (HKG:0897) expects an attributable profit of up to HK$3 million for the six months ended Sept. 30, down from HK$23.7 million a year prior, a Monday Hong Kong bourse filing said.

The drug company attributed the forecast to a 7% drop in revenue, a significant decline in net gains on the disposal of properties, and a reduction in net fair value gains on investment properties.